New pill shows promise for untreated brain tumor patients

NCT ID NCT04458272

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a new drug called DS-1001b in 25 people with a specific type of slow-growing brain tumor (grade II glioma) that has an IDH1 mutation. Participants have not had chemotherapy or radiation before. The goal is to see if the drug can shrink or control the tumor and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WHO GRADE II GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma grade II glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, Japan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Kyorin University Hospital

    Tokyo, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Tokyo Women's Medical University Hospital

    Tokyo, Japan